Envestnet Portfolio Solutions Inc. Lowers Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Envestnet Portfolio Solutions Inc. decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 49.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,262 shares of the medical equipment provider’s stock after selling 3,158 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Zimmer Biomet were worth $297,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in Zimmer Biomet by 0.7% during the first quarter. Vanguard Group Inc. now owns 23,052,925 shares of the medical equipment provider’s stock worth $2,609,130,000 after buying an additional 166,763 shares during the period. Dodge & Cox lifted its holdings in Zimmer Biomet by 2.3% during the first quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider’s stock worth $2,214,305,000 after buying an additional 446,018 shares during the period. Ameriprise Financial Inc. lifted its holdings in Zimmer Biomet by 236.0% during the first quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock worth $517,039,000 after buying an additional 3,208,596 shares during the period. JPMorgan Chase & Co. lifted its holdings in Zimmer Biomet by 251.3% during the first quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock worth $235,571,000 after buying an additional 1,488,918 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in Zimmer Biomet by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 2,058,898 shares of the medical equipment provider’s stock worth $233,009,000 after buying an additional 58,060 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on ZBH shares. Roth Capital restated a “buy” rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Stifel Nicolaus upped their target price on Zimmer Biomet from $115.00 to $118.00 and gave the stock a “buy” rating in a report on Friday, September 19th. Rothschild & Co Redburn started coverage on Zimmer Biomet in a research report on Thursday, September 18th. They set a “buy” rating and a $130.00 price target on the stock. Redburn Partners set a $130.00 price target on Zimmer Biomet in a research report on Thursday, September 18th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and a consensus target price of $111.94.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $103.13 on Friday. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The business’s fifty day simple moving average is $101.86 and its 200-day simple moving average is $97.71. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.22 and a 12-month high of $114.72. The company has a market cap of $20.43 billion, a PE ratio of 25.09, a PEG ratio of 2.39 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. During the same period in the prior year, the firm earned $2.01 EPS. The firm’s revenue was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 23.36%.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the sale, the senior vice president directly owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. This trade represents a 18.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.39% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.